(INDIANAPOLIS, July 7, 2020) — hc1, the bioinformatics leader in precision testing and prescribing, announced key COVID-19 patient findings today. Using anonymized SARS-COV-2 (the virus that causes COVID-19) test results and patient survey data gathered by Eli Lilly and Company (Lilly) through their free drive-through testing site between April 6 and May 22, 2020, hc1 created the Lilly COVID-19 Drive-Through Testing Dashboard to highlight pandemic trends in Central Indiana among health care workers, first responders, on-site essential workers, and individuals deemed to be at a higher risk for complications from the virus. To date, it is the most comprehensive COVID-19 analytics dataset available for the Central Indiana community.


“In support of Central Indiana’s response to the COVID-19 pandemic, Lilly stepped up in a major way to provide urgently needed testing for first-responders, health care workers, and vulnerable populations,” said Brad Bostic, CEO of hc1. “To maximize the impact of this testing in our community and across the country, hc1 collaborated with Lilly to deliver a publicly available dashboard that displays key insights on the symptoms of COVID-19 and the job types of individuals who are most likely to become infected.”

When booking an appointment, patients were asked a series of questions including their occupation, symptoms, and reason for seeking testing. Of the nearly 25,000 tests performed via Lilly’s drive-through site, more than 14,000 corresponding patient responses were anonymized and analyzed. To make these important insights available to the public, this data was displayed in an easy-to-use dashboard. The insights Lilly and hc1 are sharing contain a cross-section of attributes that offer a unique glimpse into the pandemic’s spread across Central Indiana that has not previously been made available by public health sources. 

Key findings include:

  • The most frequent pre-existing conditions were chronic lung disease and diabetes, with positive rates for COVID-19 of 14.2% and 17.6%, respectively
  • Nurses tested positive over twice as frequently as physicians (18.2% vs. 7.8%, respectively)
  • Of the six symptoms collected, coughing was the most common among those who tested positive for COVID-19 at 60.9%, while shortness of breath was the least common among this group at 31.5%
  • A loss of taste or smell was the most frequent indicator of infection with a 33.7% positive rate 
  • The detected rate increased with the number of symptoms reported, with 31.3% of patients with six symptoms testing positive 

“Understanding the symptoms of patients is critical as we continue to better understand COVID-19,” said Daniel Skovronsky, M.D., Ph.D., Lilly’s chief scientific officer and president of Lilly Research Laboratories. “We partnered with hc1 to share key insights about COVID-19 in our community as we continue to fight this disease.”

The public-facing Lilly COVID-19 Drive-Through Testing Dashboard, powered by hc1, is available at https://lilly.cv19dashboard.org and includes a User Guide that provides an overview of the metrics visualized in the dashboard. 

The national CV19 Lab Testing Dashboard powered by hc1 is a free public health service for individuals directly involved with implementing policies and delivering care to mitigate the spread of COVID-19. Built on the existing hc1 Platform®, the dashboard unifies lab test results across more than 20,000 lab testing locations the moment they are reported providing a critical tool for predicting surges, peaks, and declines of the COVID-19 pandemic weeks in advance.

For more information about hc1 and its CV19 Lab Testing Dashboard, please visit http://CV19dashboard.org.


Media contacts

Brittani Martel, Porch Light PR

brittani@porchlightpr.com, 317.629.1669

Jennifer Chan, Porch Light PR

jennifer@porchlightpr.com; 317.490.3770